Isofol Medical AB (publ)

DB:5IU Stock Report

Market Cap: €33.8m

Isofol Medical Management

Management criteria checks 0/4

Isofol Medical's CEO is Petter Lindqvist, appointed in Jan 2024, has a tenure of less than a year. directly owns 0.04% of the company’s shares, worth €13.66K. The average tenure of the management team and the board of directors is 0.9 years and 0.9 years respectively.

Key information

Petter Lindqvist

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownership0.04%
Management average tenureless than a year
Board average tenureless than a year

Recent management updates

Recent updates

CEO

Petter Lindqvist

less than a year

Tenure

Mr. Petter Segelman Lindqvist serves as Chief Executive Officer of Isofol Medical AB (publ) since January 09, 2024. He served as Chief Executive Officer of Hamlet BioPharma AB (publ) (formerly known as Ham...

Leadership Team

NamePositionTenureCompensationOwnership
Petter Lindqvist
Chief Executive Officerless than a yearno data0.040%
€ 13.7k
Margareta Hagman
Chief Financial Officerless than a yearno datano data
Roger Tell
Chief Medical Officerless than a yearno datano data

0.9yrs

Average Tenure

Experienced Management: 5IU's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Jan-Eric Österlund
Independent Chairmanless than a yearSEK 996.00k0.40%
€ 133.8k
Sten Nilsson
Independent Directorless than a yearno data0.0019%
€ 648.2
Lars Lind
Independent Directorless than a yearSEK 29.00k0.25%
€ 85.2k
Alain Herrera
Independent Directorless than a yearSEK 271.00kno data
Helena Taflin
Independent Directorless than a yearno datano data

0.9yrs

Average Tenure

77.5yo

Average Age

Experienced Board: 5IU's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 11:49
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Isofol Medical AB (publ) is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ulrik TrattnerCarnegie Investment Bank AB
Ole-Andreas KrohnDNB Markets
David MartinssonDNB Markets